1
|
Ferris CF. Applications in Awake Animal Magnetic Resonance Imaging. Front Neurosci 2022; 16:854377. [PMID: 35450017 PMCID: PMC9017993 DOI: 10.3389/fnins.2022.854377] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 03/09/2022] [Indexed: 12/16/2022] Open
Abstract
There are numerous publications on methods and applications for awake functional MRI across different species, e.g., voles, rabbits, cats, dogs, and rhesus macaques. Each of these species, most obviously rhesus monkey, have general or unique attributes that provide a better understanding of the human condition. However, much of the work today is done on rodents. The growing number of small bore (≤30 cm) high field systems 7T- 11.7T favor the use of small animals. To that point, this review is primarily focused on rodents and their many applications in awake function MRI. Applications include, pharmacological MRI, drugs of abuse, sensory evoked stimuli, brain disorders, pain, social behavior, and fear.
Collapse
|
2
|
Quintero JE, Ai Y, Andersen AH, Hardy P, Grondin R, Guduru Z, Gash DM, Gerhardt GA, Zhang Z. Validations of apomorphine-induced BOLD activation correlations in hemiparkinsonian rhesus macaques. NEUROIMAGE-CLINICAL 2019; 22:101724. [PMID: 30822717 PMCID: PMC6396014 DOI: 10.1016/j.nicl.2019.101724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 02/08/2019] [Accepted: 02/16/2019] [Indexed: 11/27/2022]
Abstract
Identification of Parkinson's disease at the earliest possible stage of the disease may provide the best opportunity for the use of disease modifying treatments. However, diagnosing the disease during the pre-symptomatic period remains an unmet goal. To that end, we used pharmacological MRI (phMRI) to assess the function of the cortico-basal ganglia circuit in a non-human primate model of dopamine deficiency to determine the possible relationships between phMRI signals with behavioral, neurochemical, and histological measurements. Animals with unilateral treatments with the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), that expressed stable, long-term hemiparkinsonism were challenged with the dopaminergic receptor agonist, apomorphine, and structure-specific phMRI blood oxygen level-dependent (BOLD) activation responses were measured. Behavioral, histopathological, and neurochemical measurements were obtained and correlated with phMRI activation of structures of the cortico-basal ganglia system. Greater phMRI activations in the basal ganglia and cortex were associated with slower movement speed, decreased daytime activity, or more pronounced parkinsonian features. Animals showed decreased stimulus-evoked dopamine release in the putamen and substantia nigra pars compacta and lower basal glutamate levels in the motor cortex on the MPTP-lesioned hemisphere compared to the contralateral hemisphere. The altered neurochemistry was significantly correlated with phMRI signals in the motor cortex and putamen. Finally, greater phMRI activations in the caudate nucleus correlated with fewer tyrosine hydroxylase-positive (TH+) nigral cells and decreased TH+ fiber density in the putamen. These results reveal the correlation of phMRI signals with the severity of the motor deficits and pathophysiological changes in the cortico-basal ganglia circuit. Apomorphine in hemiparkinsonian animals can evoke changes in functional MRI signals. Cortico-basal ganglia activation correlates to behavior, neurochemistry, histology Pharmacological MRI has potential to be biomarker for Parkinson's disease.
Collapse
Affiliation(s)
- J E Quintero
- Department of Neuroscience, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - Yi Ai
- Department of Neuroscience, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - A H Andersen
- Department of Neuroscience, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA; Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - P Hardy
- Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - R Grondin
- Department of Neuroscience, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - Z Guduru
- Department of Neurology, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - D M Gash
- Department of Neuroscience, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - G A Gerhardt
- Department of Neuroscience, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA
| | - Z Zhang
- Department of Neuroscience, University of Kentucky Chandler Medical Center, Lexington, KY 40536-0098, USA.
| |
Collapse
|
3
|
Zhang R, Andersen AH, Hardy PA, Forman E, Evans A, Ai Y, Yue J, Yue G, Gash DM, Grondin R, Zhang Z. Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys. Brain Res 2017; 1678:12-19. [PMID: 29017909 DOI: 10.1016/j.brainres.2017.10.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2017] [Revised: 09/19/2017] [Accepted: 10/04/2017] [Indexed: 01/12/2023]
Abstract
Acupuncture has increasingly been used as an alternative therapy for treatment of Parkinson's disease (PD). However, the efficacy of acupunture for PD still remains unclear. The present study was designed to objectively and safely monitor anti-parkinsonian effects of electroacupuncture (EA) and brain activity in nonhuman primates modeling human PD. Six middle-aged rhesus monkeys were extensively studied by a computerized behavioral testing battery and by pharmacological MRI (phMRI) scans with specific dopaminergic drug stimulations. All animals were evaluated for behavior and phMRI responses under normal, parkinsonian, parkinsonian with EA treatment and parkinsonian after EA treatment conditions. Stable parkinsonian features were observed in all animals prior to entering the EA study and positive responses to levodopa (L-dopa) challenge were also seen in all animals. The results demonstrated that chronic EA treatments could significantly improve the movement speed and the fine motor performance time during the period of EA treatments, and the effectiveness of EA could be detected even 3 months after the EA treatment. The phMRI data revealed that chronic EA treatments could alter neuronal activity in the striatum, primary motor cortex (M1), cingulate gyrus and global pallidus externa (GPe) in the ipsilateral hemisphere to MPTP lesions. As seen in the changes of parkinsonian features, the residual effects of phMRI responses to apomorphine (APO) challenge could also be found in the aforementioned areas. The results strongly suggest that anti-parkinsonian effects of EA can be objectively assessed, and the method used in the present study could be translated into the human clinic with some minor modifications.
Collapse
Affiliation(s)
- Rui Zhang
- Department of Neurosurgery, Shandong Provincial Hospital, Shandong University, School of Medicine, Jinan, Shandong 250021 PR China; Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - Anders H Andersen
- Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington, KY 40536, USA; Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - Peter A Hardy
- Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington, KY 40536, USA; Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - Eric Forman
- Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - April Evans
- Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - Yi Ai
- Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - Jin Yue
- Nanning Hospital of Traditional Chinese Medicine, Nanning City, Guangxi 530001, PR China
| | - Guihua Yue
- Guangxi University of Chinese Medicine, Nanning City, Guangxi 530200, PR China
| | - Don M Gash
- Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - Richard Grondin
- Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - Zhiming Zhang
- Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
| |
Collapse
|
4
|
Tuite P. Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD). Brain Sci 2017; 7:E68. [PMID: 28621758 PMCID: PMC5483641 DOI: 10.3390/brainsci7060068] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 06/09/2017] [Accepted: 06/13/2017] [Indexed: 12/14/2022] Open
Abstract
Magnetic resonance imaging (MRI) has the potential to serve as a biomarker for Parkinson's disease (PD). However, the type or types of biomarker it could provide remain to be determined. At this time there is not sufficient sensitivity or specificity for MRI to serve as an early diagnostic biomarker, i.e., it is unproven in its ability to determine if a single individual is normal, has mild PD, or has some other forms of degenerative parkinsonism. However there is accumulating evidence that MRI may be useful in staging and monitoring disease progression (staging biomarker), and also possibly as a means to monitor pathophysiological aspects of disease and associated response to treatments, i.e., theranostic marker. As there are increasing numbers of manuscripts that are dedicated to diffusion- and neuromelanin-based imaging methods, this review will focus on these topics cursorily and will delve into pharmacodynamic imaging as a means to get at theranostic aspects of PD.
Collapse
Affiliation(s)
- Paul Tuite
- Neurology Department, University of Minnesota, MMC 295, 420 Delaware St SE, Minneapolis, MN 55455, USA.
| |
Collapse
|
5
|
Tuite P. Magnetic resonance imaging as a potential biomarker for Parkinson's disease. Transl Res 2016; 175:4-16. [PMID: 26763585 DOI: 10.1016/j.trsl.2015.12.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Revised: 12/09/2015] [Accepted: 12/10/2015] [Indexed: 01/01/2023]
Abstract
Although a magnetic resonance imaging (MRI) biomarker for Parkinson's disease (PD) remains an unfulfilled objective, there have been numerous developments in MRI methodology and some of these have shown promise for PD. With funding from the National Institutes of Health and the Michael J Fox Foundation there will be further validation of structural, diffusion-based, and iron-focused MRI methods as possible biomarkers for PD. In this review, these methods and other strategies such as neurochemical and metabolic MRI have been covered. One of the challenges in establishing a biomarker is in the selection of individuals as PD is a heterogeneous disease with varying clinical features, different etiologies, and a range of pathologic changes. Additionally, longitudinal studies are needed of individuals with clinically diagnosed PD and cohorts of individuals who are at great risk for developing PD to validate methods. Ultimately an MRI biomarker will be useful in the diagnosis of PD, predicting the course of PD, providing a means to track its course, and provide an approach to select and monitor treatments.
Collapse
Affiliation(s)
- Paul Tuite
- Department of Neurology, University of Minnesota, Minneapolis, Minnesota.
| |
Collapse
|
6
|
Lanfermann H, Schindler C, Jordan J, Krug N, Raab P. Pharmacological MRI (phMRI) of the Human Central Nervous System. Clin Neuroradiol 2015; 25 Suppl 2:259-66. [DOI: 10.1007/s00062-015-0457-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Accepted: 08/12/2015] [Indexed: 01/09/2023]
|
7
|
Bannon D, Landau AM, Doudet DJ. How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease? Curr Neurol Neurosci Rep 2015; 15:53. [DOI: 10.1007/s11910-015-0571-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|